European Neuropsychopharmacology, ISSN 0924-977X, 10/2017, Volume 27, pp. S862 - S863
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2018, Volume 8, Issue 1, pp. 13382 - 8
Genomic imbalances are the most common cause of congenital anomalies (CA) and intellectual disability (ID). The aims of this study were to identify copy number...
INDIVIDUALS | CHROMOSOMAL MICROARRAY | ETIOLOGY | MENTAL-RETARDATION | CLINICAL UTILITY | MULTIDISCIPLINARY SCIENCES | MICRODELETION SYNDROMES | DEVELOPMENTAL-DISABILITIES | REARRANGEMENTS | IDENTIFICATION | ARRAY CGH | Variation | Congenital defects | Intellectual disabilities | Copy number | Genotypes
INDIVIDUALS | CHROMOSOMAL MICROARRAY | ETIOLOGY | MENTAL-RETARDATION | CLINICAL UTILITY | MULTIDISCIPLINARY SCIENCES | MICRODELETION SYNDROMES | DEVELOPMENTAL-DISABILITIES | REARRANGEMENTS | IDENTIFICATION | ARRAY CGH | Variation | Congenital defects | Intellectual disabilities | Copy number | Genotypes
Journal Article
Journal of Hepatology, ISSN 0168-8278, 12/2019, Volume 71, Issue 6, pp. 1106 - 1115
Sofosbuvir/velpatasivr/voxilaprevir (SOF/VEL/VOX) is approved for retreatment of patients with HCV and a previous failure on direct-acting antivirals (DAAs),...
Resistance | Retreatment | HCV | RAS | Sofosbuvir | Direct-acting antivirals | VIRUS-INFECTION | RIBAVIRIN | REGIMENS | THERAPY | NS5A | SOFOSBUVIR-VELPATASVIR-VOXILAPREVIR | EXPERIENCED PATIENTS | GASTROENTEROLOGY & HEPATOLOGY | GLECAPREVIR/PIBRENTASVIR
Resistance | Retreatment | HCV | RAS | Sofosbuvir | Direct-acting antivirals | VIRUS-INFECTION | RIBAVIRIN | REGIMENS | THERAPY | NS5A | SOFOSBUVIR-VELPATASVIR-VOXILAPREVIR | EXPERIENCED PATIENTS | GASTROENTEROLOGY & HEPATOLOGY | GLECAPREVIR/PIBRENTASVIR
Journal Article
PharmacoEconomics, ISSN 1170-7690, 02/2019, Volume 37, Issue 2, pp. 255 - 266
ObjectiveWe estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C...
COST-EFFECTIVENESS | VIRUS-INFECTION | METAANALYSIS | MANAGEMENT | CHRONIC HEPATITIS-C | LIVER FIBROSIS | FIBROSIS PROGRESSION | HEALTH CARE SCIENCES & SERVICES | INDUCED DISEASES | PHARMACOLOGY & PHARMACY | HEALTH POLICY & SERVICES | ERADICATION | ECONOMICS | OUTBREAK
COST-EFFECTIVENESS | VIRUS-INFECTION | METAANALYSIS | MANAGEMENT | CHRONIC HEPATITIS-C | LIVER FIBROSIS | FIBROSIS PROGRESSION | HEALTH CARE SCIENCES & SERVICES | INDUCED DISEASES | PHARMACOLOGY & PHARMACY | HEALTH POLICY & SERVICES | ERADICATION | ECONOMICS | OUTBREAK
Journal Article
The American Journal of Human Genetics, ISSN 0002-9297, 08/2019, Volume 105, Issue 2, pp. 267 - 282
Sequencing-based studies have identified novel risk genes associated with severe epilepsies and revealed an excess of rare deleterious variation in less-severe...
epilepsy | seizures | exome | epileptic encephalopathy | burden analysis | sequencing | PROTEIN | METAANALYSIS | DE-NOVO MUTATIONS | VARIANTS | SUSCEPTIBILITY | GENETICS & HEREDITY | EPILEPTIC SEIZURES | GAMMA-2-SUBUNIT | GENOME | EPIDEMIOLOGY | COMMON EPILEPSIES | Psychological aspects | Genetic variation | Epilepsy | Physiological aspects | Genetic aspects | Research | Risk factors
epilepsy | seizures | exome | epileptic encephalopathy | burden analysis | sequencing | PROTEIN | METAANALYSIS | DE-NOVO MUTATIONS | VARIANTS | SUSCEPTIBILITY | GENETICS & HEREDITY | EPILEPTIC SEIZURES | GAMMA-2-SUBUNIT | GENOME | EPIDEMIOLOGY | COMMON EPILEPSIES | Psychological aspects | Genetic variation | Epilepsy | Physiological aspects | Genetic aspects | Research | Risk factors
Journal Article
BJOG: An International Journal of Obstetrics & Gynaecology, ISSN 1470-0328, 07/2017, Volume 124, Issue 8, pp. 1218 - 1223
Objectives To assess in pregnant women with HIV the rates of amniocentesis and chorionic villus sampling (CVS), and the outcomes associated with such...
Amniocentesis | chorionic villus sampling | HIV | pregnancy | invasive testing | motherâto child HIV transmission | prenatal diagnosis | birth defects | mother-to child HIV transmission | DIAGNOSIS | RISK-FACTORS | OBSTETRICS & GYNECOLOGY | RATES | TO-CHILD TRANSMISSION | Anti-Retroviral Agents - therapeutic use | Fetal Death - etiology | Pregnancy Complications, Infectious - virology | Humans | Chi-Square Distribution | Amniocentesis - adverse effects | Pregnancy | Chorionic Villi Sampling - adverse effects | Analysis of Variance | Pregnancy Complications, Infectious - drug therapy | Adult | Female | HIV Infections - drug therapy | HIV Infections - transmission | Infectious Disease Transmission, Vertical - statistics & numerical data | Odds Ratio | Antiviral agents | HIV patients | Birth defects | Chorionic villus sampling | HIV (Viruses) | HIV infection in pregnancy | Highly active antiretroviral therapy | Pregnant women | Analysis | HIV testing | HIV infection | Neonates | Disease transmission | Fetuses | Human immunodeficiency virus--HIV | Death | Villus | Sampling | Medical screening
Amniocentesis | chorionic villus sampling | HIV | pregnancy | invasive testing | motherâto child HIV transmission | prenatal diagnosis | birth defects | mother-to child HIV transmission | DIAGNOSIS | RISK-FACTORS | OBSTETRICS & GYNECOLOGY | RATES | TO-CHILD TRANSMISSION | Anti-Retroviral Agents - therapeutic use | Fetal Death - etiology | Pregnancy Complications, Infectious - virology | Humans | Chi-Square Distribution | Amniocentesis - adverse effects | Pregnancy | Chorionic Villi Sampling - adverse effects | Analysis of Variance | Pregnancy Complications, Infectious - drug therapy | Adult | Female | HIV Infections - drug therapy | HIV Infections - transmission | Infectious Disease Transmission, Vertical - statistics & numerical data | Odds Ratio | Antiviral agents | HIV patients | Birth defects | Chorionic villus sampling | HIV (Viruses) | HIV infection in pregnancy | Highly active antiretroviral therapy | Pregnant women | Analysis | HIV testing | HIV infection | Neonates | Disease transmission | Fetuses | Human immunodeficiency virus--HIV | Death | Villus | Sampling | Medical screening
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 01/2018, Volume 73, Issue 4, pp. 1025 - 1030
Background: Atazanavir and darunavir represent the main HIV PIs recommended in pregnancy, but comparative data in pregnant women are limited. We assessed the...
INFECTIOUS DISEASES | MANAGEMENT | PROFILE | RALTEGRAVIR | CASTLE | ONCE-DAILY ATAZANAVIR/RITONAVIR | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | TWICE-DAILY LOPINAVIR/RITONAVIR | DARUNAVIR/RITONAVIR | INFECTION | LIPOPROTEINS | Anti-HIV Agents - adverse effects | Atazanavir Sulfate - administration & dosage | Cholesterol - blood | Humans | Infant | Male | Treatment Outcome | Alanine Transaminase - blood | Atazanavir Sulfate - adverse effects | Viral Load | Drug-Related Side Effects and Adverse Reactions - epidemiology | Drug-Related Side Effects and Adverse Reactions - pathology | Anti-HIV Agents - administration & dosage | Pregnancy | Bilirubin - blood | Darunavir - administration & dosage | Pregnancy Complications, Infectious - drug therapy | Triglycerides - blood | Adult | Female | HIV Infections - drug therapy | Darunavir - adverse effects | Infant, Newborn | Pregnancy Outcome
INFECTIOUS DISEASES | MANAGEMENT | PROFILE | RALTEGRAVIR | CASTLE | ONCE-DAILY ATAZANAVIR/RITONAVIR | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | TWICE-DAILY LOPINAVIR/RITONAVIR | DARUNAVIR/RITONAVIR | INFECTION | LIPOPROTEINS | Anti-HIV Agents - adverse effects | Atazanavir Sulfate - administration & dosage | Cholesterol - blood | Humans | Infant | Male | Treatment Outcome | Alanine Transaminase - blood | Atazanavir Sulfate - adverse effects | Viral Load | Drug-Related Side Effects and Adverse Reactions - epidemiology | Drug-Related Side Effects and Adverse Reactions - pathology | Anti-HIV Agents - administration & dosage | Pregnancy | Bilirubin - blood | Darunavir - administration & dosage | Pregnancy Complications, Infectious - drug therapy | Triglycerides - blood | Adult | Female | HIV Infections - drug therapy | Darunavir - adverse effects | Infant, Newborn | Pregnancy Outcome
Journal Article
PharmacoEconomics, 02/2019, Volume 37, Issue 2, p. 255
We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus...
Journal Article
Nature Communications, ISSN 2041-1723, 2019, Volume 10, Issue 1, pp. 3094 - 16
AMPA receptors (AMPARs) are tetrameric ligand-gated channels made up of combinations of GluA1-4 subunits encoded by GRIA1-4 genes. GluA2 has an especially...
INTELLECTUAL DISABILITY | GRIN2A | DE-NOVO MUTATIONS | RETT-SYNDROME | MECHANISM | MULTIDISCIPLINARY SCIENCES | DEFICIENT | PHENOTYPE | MICE | EPILEPSY | GLUR2 | Electric potential | Post-transcription | Calcium | Abnormalities | Epilepsy | Disorders | Îą-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors | Neurodevelopmental disorders | Channels | Autism | Receptors | Synaptic transmission | Îą-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid | Encephalopathy | Rett syndrome | Voltage | Glutamatergic transmission | Mutation | Calcium ions | Seizures
INTELLECTUAL DISABILITY | GRIN2A | DE-NOVO MUTATIONS | RETT-SYNDROME | MECHANISM | MULTIDISCIPLINARY SCIENCES | DEFICIENT | PHENOTYPE | MICE | EPILEPSY | GLUR2 | Electric potential | Post-transcription | Calcium | Abnormalities | Epilepsy | Disorders | Îą-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors | Neurodevelopmental disorders | Channels | Autism | Receptors | Synaptic transmission | Îą-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid | Encephalopathy | Rett syndrome | Voltage | Glutamatergic transmission | Mutation | Calcium ions | Seizures
Journal Article
10.
Full Text
Pregnancy outcomes and cytomegalovirus DNAaemia in HIV-infected pregnant women with CMV
Clinical Microbiology and Infection, ISSN 1198-743X, 09/2016, Volume 22, Issue 9, pp. 818 - 820
Journal Article
HIV Medicine, ISSN 1464-2662, 07/2017, Volume 18, Issue 6, pp. 440 - 443
Objectives The aim of the study was to assess the rate, determinants, and outcomes of repeat pregnancies in women with HIV infection. Methods Data from a...
birth weight | HIV | HIV RNA | preterm delivery | pregnancy | INFECTIOUS DISEASES | PREDICTORS | Infant, Low Birth Weight | HIV Infections - virology | Humans | CD4 Lymphocyte Count | Premature Birth - epidemiology | Viral Load | Pregnancy | HIV Infections - immunology | HIV-1 - physiology | HIV Infections - complications | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Emigrants and Immigrants | Prevention | Highly active antiretroviral therapy | Medical research | RNA | Pregnant women | Medicine, Experimental | Development and progression | HIV patients | HIV (Viruses) | HIV infection | Childbirth | Antiretroviral drugs | Load distribution | Infections | Ribonucleic acid--RNA | Disease control | CD4 antigen | Childbirth & labor | Confidence intervals | Womens health | Antiretroviral agents | Human immunodeficiency virus--HIV | Birth weight | Children
birth weight | HIV | HIV RNA | preterm delivery | pregnancy | INFECTIOUS DISEASES | PREDICTORS | Infant, Low Birth Weight | HIV Infections - virology | Humans | CD4 Lymphocyte Count | Premature Birth - epidemiology | Viral Load | Pregnancy | HIV Infections - immunology | HIV-1 - physiology | HIV Infections - complications | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Emigrants and Immigrants | Prevention | Highly active antiretroviral therapy | Medical research | RNA | Pregnant women | Medicine, Experimental | Development and progression | HIV patients | HIV (Viruses) | HIV infection | Childbirth | Antiretroviral drugs | Load distribution | Infections | Ribonucleic acid--RNA | Disease control | CD4 antigen | Childbirth & labor | Confidence intervals | Womens health | Antiretroviral agents | Human immunodeficiency virus--HIV | Birth weight | Children
Journal Article